News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
26,255 Results
Type
Article (3967)
Company Profile (4)
Press Release (22284)
Multimedia
Podcasts (32)
Webinars (4)
Section
Business (9831)
Career Advice (39)
Deals (1260)
Drug Delivery (24)
Drug Development (4468)
Employer Resources (12)
FDA (737)
Job Trends (1080)
News (14995)
Policy (1563)
Tag
2027 BioCapital Standard (1)
Academia (81)
Accelerated approval (1)
Adcomms (2)
Allergies (2)
Alliances (2273)
ALS (3)
Alzheimer's disease (42)
Antibody-drug conjugate (ADC) (115)
Approvals (753)
Artificial intelligence (28)
ASCO (66)
Autoimmune disease (14)
Automation (2)
Bankruptcy (9)
Best Places to Work (846)
BIO (1)
BIOSECURE Act (7)
Biosimilars (12)
BioSpace Insights (6)
Biotechnology (1)
Bladder cancer (26)
Brain cancer (11)
Breast cancer (82)
Cancer (597)
Cardiovascular disease (47)
Career advice (43)
Career pathing (2)
CAR-T (12)
CDC (14)
Cell therapy (24)
Cervical cancer (8)
Clinical research (3836)
Collaboration (106)
Company closure (4)
Compensation (7)
Complete response letters (7)
COVID-19 (206)
CRISPR (3)
C-suite (115)
Cystic fibrosis (2)
Data (284)
Depression (4)
Dermatology (2)
Diabetes (7)
Diagnostics (98)
Digital health (2)
Diversity, equity & inclusion (3)
Drug discovery (18)
Drug pricing (50)
Drug shortages (1)
Duchenne muscular dystrophy (7)
Earnings (2344)
Editorial (10)
Employer branding (6)
Employer resources (12)
Events (2572)
Executive appointments (106)
FDA (864)
Funding (68)
Gene editing (10)
Generative AI (3)
Gene therapy (17)
GLP-1 (83)
Government (336)
Grass and pollen (1)
Guidances (8)
Healthcare (485)
Hematology (7)
HIV (20)
Huntington's disease (2)
IgA nephropathy (3)
Immunology and inflammation (38)
Immuno-oncology (22)
Indications (16)
Infectious disease (238)
Inflammatory bowel disease (12)
Inflation Reduction Act (4)
Influenza (1)
Intellectual property (7)
Interviews (2)
IPO (376)
IRA (12)
Job creations (284)
Job search strategy (39)
JPM (9)
Kidney cancer (6)
Labor market (11)
Layoffs (68)
Leadership (2)
Legal (402)
Liver cancer (8)
Longevity (1)
Lung cancer (143)
Lymphoma (15)
Machine learning (2)
Management (4)
Manufacturing (57)
MASH (8)
Medical device (83)
Medtech (84)
Mergers & acquisitions (930)
Metabolic disorders (54)
mRNA (38)
Multiple sclerosis (14)
Neurodegenerative disease (20)
Neuropsychiatric disorders (10)
Neuroscience (92)
NextGen: Class of 2026 (200)
Non-profit (92)
Now hiring (3)
Obesity (37)
Opinion (38)
Ovarian cancer (27)
Pain (6)
Pancreatic cancer (11)
Parkinson's disease (5)
Patents (24)
Patient recruitment (14)
People (4028)
Pharmaceutical (2)
Pharmacy benefit managers (3)
Phase 1 (1096)
Phase 2 (1709)
Phase 3 (1613)
Pipeline (364)
Policy (63)
Postmarket research (201)
Preclinical (278)
Press Release (2)
Prostate cancer (7)
Psychedelics (9)
Radiopharmaceuticals (18)
Rare diseases (37)
Real estate (213)
Recruiting (4)
Regulatory (1132)
Reports (7)
Research institute (74)
Resumes & cover letters (1)
RNA editing (2)
RSV (18)
Schizophrenia (4)
Series A (17)
Series B (11)
Sickle cell disease (3)
Special edition (7)
Spinal muscular atrophy (4)
Sponsored (2)
Startups (214)
Stomach cancer (9)
Supply chain (9)
Tariffs (23)
The Weekly (30)
Vaccines (164)
Venture capital (16)
Weight loss (32)
Women's health (5)
Worklife (1)
Date
Today (5)
Last 7 days (20)
Last 30 days (98)
Last 365 days (1024)
2026 (637)
2025 (1024)
2024 (1236)
2023 (1319)
2022 (2974)
2021 (2787)
2020 (2291)
2019 (1546)
2018 (1196)
2017 (1348)
2016 (1159)
2015 (1327)
2014 (867)
2013 (725)
2012 (785)
2011 (880)
2010 (816)
Location
Africa (65)
Alabama (4)
Alaska (1)
Arizona (3)
Asia (1630)
Australia (405)
California (288)
Canada (104)
China (137)
Colorado (6)
Connecticut (8)
Delaware (15)
Europe (4426)
Florida (72)
Georgia (3)
Illinois (13)
India (3)
Indiana (2)
Japan (70)
Kansas (1)
Kentucky (1)
Maryland (69)
Massachusetts (303)
Michigan (1)
Minnesota (5)
Mississippi (1)
Missouri (4)
Montana (1)
Nevada (2)
New Hampshire (5)
New Jersey (343)
New York (98)
North Carolina (26)
Northern California (156)
Ohio (3)
Oregon (1)
Pennsylvania (32)
Rhode Island (4)
South America (61)
Southern California (104)
Tennessee (2)
Texas (32)
United States (1330)
Utah (8)
Virginia (8)
Washington D.C. (5)
Washington State (32)
West Virginia (1)
Wisconsin (3)
26,255 Results for "merck kgaa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
M&A
Merck KGaA inks $11B Bio-Techne buyout to expand into cell therapy production
The company is “especially excited” about an immune cell therapy manufacturing technology included in the deal, a Merck KGaA executive said.
June 26, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development
July 29, 2026
·
3 min read
Press Releases
Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
June 25, 2026
·
18 min read
Press Releases
Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
June 24, 2026
·
4 min read
Press Releases
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
May 21, 2026
·
7 min read
Earnings
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
The anti-TL1A antibody from Merck’s 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside second-quarter earnings.
August 4, 2026
·
3 min read
·
Gabrielle Masson
People
Sanofi Shares Decline as Paul Hudson Removed as CEO, Making Way For Merck KGaA’s Belén Garijo
The sudden departure stands in contrast to other EU pharma leaders who have been given much longer transitions in recent months, including GSK’s Emma Walmsley and Novo Nordisk’s Lars Fruergaard Jørgensen.
February 12, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
aptaTargets transferred ApTOLL to Merck KGaA, Darmstadt, Germany
ApTOLL completed a Phase 1b/2 clinical trial for acute ischemic stroke with positive results. Merck KGaA, Darmstadt, Germany, to assume clinical development and commercialization of ApTOLL.
May 22, 2025
·
1 min read
Press Releases
Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
April 30, 2026
·
7 min read
Approvals
Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
July 16, 2026
·
2 min read
·
Gabrielle Masson
1 of 2,626
Next
